In one specific case, an antibody was created to attack the protein TNFR2 that is common in large amounts of tumor cells. Interestingly enough it is also found on an immune cells that prevents the immune system of a person with cancer from attacking the cancer. In the study the researchers used the TNFR2 antibodies to treat ovarian cancer (NCI Staff 2017). Dr. Farkas’ research is both alike and different from this research in that it utilizes a delivery system to target NPSCs to markers of cancer antigens, using a co-delivery system of therapy just as ADCs do. Once again, if the biomolecular process is completely understood, recent ADC application has proven that such nanoparticle stabilized capsules made from gold and nucleic acids at least in theory will be effective. Thus, the same ideological methodology is being utilized already in medicine, but this process could prove to be more safe and useful due to the material of the delivery system.
Recent comments